Press Releases

 
Press Releases
  Date Title View
Jul 31, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced its intention to offer, subject to market conditions and other factors, $175 million aggregate principal amount of convertible senior notes due 2025 (the "Notes") in a private placement to qualified ...
Jul 26, 2017
Royalties earned up 73% and net income up 141% compared to second quarter of 2016 Management to host a conference call and webcast today at 5:00 p.m. Eastern time BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the Company) toda...
Jul 21, 2017
LONDON--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting ^...
Jul 19, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the second quarter ended June 30, 2017 after market close on Wednesday, July 26, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at ...
May 10, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, and Eric d'Esparbes, the Company's Senior Vice President and Chief Financial Officer, will participate in a fireside chat at the Bank of America Merr...
May 5, 2017
Primary endpoint showed patients initiated with Relvar Ellipta had twice the odds of achieving an improvement in asthma control compared with patients continuing usual care. LONDON--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva Inc (NASDAQ: INVA) today announced...
Apr 27, 2017
Royalties earned in Q1 2017 of $43.7 million, up 60% from Q1 2016 Net income for Q1 2017 of $16.8 million (up 280% from Q1 2016), or $0.16 basic earnings per share, and adjusted earnings per share of $0.19 per share Management will host a conference call and webcast...
Apr 21, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the first quarter ended March 31, 2017 after market close on Thursday, April 27, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at ...
Apr 20, 2017
Innoviva Shareholders Support All Seven Innoviva Board Members and Management at Annual Meeting BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) is pleased to announce that, based on the advice of its proxy solicitor, the Company believ...
Apr 19, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today called upon shareholders to make the clear choice to vote FOR the Company's Board of Directors (the "Board"). The Annual Meeting of Stockholders is scheduled to be held tomorrow, April 20, 2017, but there is stil...
FirstPrevious
2
...
NextLast
= add release to Briefcase

Innoviva NASDAQ: INVA

$13.78 0.29 (2.15%) 09/22/17 4:00 PM ET Refresh Quote

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.